Back to today’s briefing

Story perspectives

Immunovant Shifts Focus to Promising New Drug IMVT-1402

3/19/2025

50 11

Summary

Story summary

Immunovant's groundbreaking antibody treatment, batoclimab, brought hope to myasthenia gravis patients, showcasing impressive symptom relief during a Phase 3 trial with notable score improvements. However, the company has decided against pursuing regulatory approval for batoclimab, shifting its focus to the promising follow-on drug, IMVT-1402, which holds even greater potential for patients.

1 of 1

Story summary

Immunovant's groundbreaking antibody treatment, batoclimab, brought hope to myasthenia gravis patients, showcasing impressive symptom relief during a Phase 3 trial with notable score improvements. However, the company has decided against pursuing regulatory approval for batoclimab, shifting its focus to the promising follow-on drug, IMVT-1402, which holds even greater potential for patients.